In healthy subjects at digoxin steady state, cardiac measurements did not differ between teriparatide and placebo coadministration.
In plain wordsIn healthy subjects taking digoxin, teriparatide and placebo had similar cardiac effects.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- No significant changeCardiac pharmacodynamic effects of digoxin
- Study
n = 15
- Comparator
- Digoxin plus placebo
- Outcome group
- Heart function · Cardiovascular
- Studied dose
- 20 microg · subcutaneous · Single doseAs given in this study (human).
Source sentences
However, there was no difference between treatment with digoxin plus placebo versus digoxin plus teriparatide.
3 context sentences(design, population, supporting numbers)
Serial systolic time interval and heart rate measurements were obtained on days 1, 15, and 16.
Fifteen healthy subjects (2 men and 13 women) were administered a single subcutaneous teriparatide dose (20 microg) on day 1 and then equilibrated on a daily oral dose of digoxin for 15 days.
Subcutaneous placebo and teriparatide, 20 microg, were given in a randomized crossover design with the 14th (day 15) and 15th (day 16) digoxin doses.